One-carbon Therapeutics AB is a clinical-stage company headquartered in Sweden
At One-carbon Therapeutics, we are committed to advancing a first-in-class MTHFD1/2 inhibitor TH9619 through clinical development. By identifying early signs of anti-tumour activity and guiding rational indication selection, we are building the foundation for a new generation of more precise and more tolerable cancer treatments.
We are driven by the belief that deep biological understanding can open the way to meaningful therapeutic progress. Working alongside leading researchers, clinicians, and technology innovators, we combine bold ambition with disciplined execution to follow the science, let the data lead, and bring better treatment possibilities to patients who need them most.
At One-carbon Therapeutics we are committed to pioneering first-in-class anti-cancer therapies that push the treatment boundaries in the field of oncology. Working alongside leading researchers, clinicians and technology innovators, we are shaping a new era of patient-focused cancer care.
Our team has extensive experience in oncology, drug discovery, and development. We are inspired by science and committed to delivering better precision medicines to patients.
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies that exploit cancer’s oncogene addition, today announced that a
Solna, Sweden, May 21, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, today announced the appointment of Stefan Larsson, MD, PhD,